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Abstract  Complex  regional  pain  syndrome  is  a  chronic  and  painful  condition  that  affects  the
quality of  life  of  patients.  It  is  usually  triggered  by  a  traumatic  event  of  the  soft  tissues  involv-
ing the  nervous  tissue.  Although  the  factors  that  cause  the  syndrome  are  varied  and  not  well
known, different  etiopathologic  concepts  have  been  proposed  to  explain  the  presence  of  this
syndrome,  such  as  autonomic  dysfunction  and  changes  in  CNS  plasticity,  among  others.  The
patient characteristically  presents  pain,  sensory  abnormalities,  vasomotor  disturbances  in  the
skin, edema,  changes  in  sweating,  and  motor  alterations.  The  pain  is  associated  with  changes
in the  autonomic  nervous  system  and  has  a  distal  predominance.  Since  there  is  no  deﬁnitive
diagnostic  test,  diagnosis  is  mainly  based  on  a  complete  medical  history  and  physical  examina-
tion. Treatment  is  multidisciplinary  and  based  on  pain  relief.  Although  in  most  cases  evolution  is
favorable,  rapid  diagnosis  and  treatment  are  recommended  to  avoid  dystrophic  stage  as  much
as possible.
© 2014  Universidad  Autónoma  de  Nuevo  León.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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he  ﬁrst  description  of  complex  regional  pain  syndrome
CRPS)  dates  from  the  seventeenth  century  and  was  reported
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ent  pain  and  contractures  of  the  arm  suffered  by  King
harles  IX  after  the  bloodletting  to  which  he  was  sub-
ected.  During  the  American  Civil  War,  Mitchell  described
ases  in  which  the  soldiers  suffered  from  burning  pain
econdary  to  gunshot  wounds.  This  was  described  as  causal-
ia.  In  1900  Sudeck  described  traumatic  complications
n  the  extremities  characterized  by  intractable  pain,
dema,  and  limitations  in  motor  function.  Lerich  in
916,  suggested  that  causalgia  was  caused  by  exces-
ive  activity  of  the  sympathetic  nervous  system.  It  was
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CComplex  regional  pain  syndrome  (CRPS),  a  review  
not  until  1946  when  Evans  proposed  reﬂex  sympathetic
dystrophy.1
In  1979  the  International  Association  for  the  Study  of
Pain  (IASP)  deﬁned  causalgia  as  ‘‘a  syndrome  of  sustained,
burning  pain  after  a  traumatic  nerve  injury,  combined  with
vasomotor  and  sudomotor  and  later  trophic  changes’’  and
reﬂex  sympathetic  dystrophy  as  ‘‘similar,  but  from  other
causes.’’1
The  term  proposed  by  the  IASP  in  1994,  which  differen-
tiates  complex  regional  pain  syndrome  into  type  1  and  2,  is
currently  used  with  the  dissimilarity  that  type  1  is  caused  by
an  injury  or  trauma  to  tissue  and  in  type  2  there  is  prior  and
obvious  neurological  damage.
Since  the  characteristics  of  these  two  types  of  disease  are
essentially  the  same  and  treatment  is  not  different,  the  rest
of  this  text  will  not  distinguish  between  them  with  respect
to  pathophysiology,  diagnosis  or  treatment.
Epidemiology
Worldwide,  the  incidence  and  prevalence  of  CRPS  is
unknown.  Some  studies  have  reported  an  incidence  rate  that
ranges  from  5.46  to  26.2  per  100,000  persons  year.2,3 In  addi-
tion,  the  prevalence  subsequent  to  trauma  ranges  from  0.03
to  37%,  based  on  retrospective  studies.  In  40%  of  cases  it  is
associated  with  a  fracture  or  surgery,  with  compression  of
the  median  nerve  being  the  most  common,  although  it  can
also  appear  after  a  sprain  (10%),  root  lesions  (9%),  lesions
of  the  spinal  cord  (6%),  and  spontaneously  (5--10%).  It  was
found  that  it  more  frequently  affects  women  (2--3:1)  with  a
peak  between  50  and  70  years  of  age,  with  a  predominance
in  the  arms.4
It  is  noteworthy  that  the  severity  of  the  original  injury  is
not  correlated  with  the  severity  of  the  symptoms  of  CRPS,
although  psychological  factors  such  as  stress  are  risk  factors
that  worsen  symptomatology.5
CRPS  is  also  associated  with  other  diseases  and  conditions
such  as  stroke,  mastectomy,  pregnancy,  and  the  use  of  drugs
such  as  phenobarbital  and  isoniazid.  There  are  predisposing
factors  for  the  development  of  this  syndrome  in  addition  to
trauma  and  diabetes  mellitus.6
The  main  feature  of  the  history  is  a  fracture,  and  immo-
bilization  has  been  proposed  as  a  possible  predisposing
factor  for  CRPS.  Immobilization  studies  in  animals  have
found  increased  sensitivity  to  stimuli,  and  changes  at  the
spinal  level.  In  humans  it  was  found  that  plaster  splint
immobilization  results  in  an  increase  in  cerebral  blood
ﬂow  in  areas  related  to  sensory,  motor,  and  emotional
processing.7
It  is  believed  that  psychogenic  or  hysterical  factors,
mainly  associated  with  depressive  symptoms,  may  con-
tribute  to  CRPS.  Any  psychological  factor  can  interact  with
catecholamine  release  and  thus  interfere  with  the  patho-
physiological  mechanisms  mentioned;  however  this  is  only  a
hypothesis.8 The  success  of  psychotherapy  and  occupational
and  cognitive  therapy  in  CRPS  patients  shows  that  the  symp-
toms  of  dystonia  and  myoclonus  are  of  a  psychogenic  origin
in  some  patients.  It  is  not  always  easy  to  distinguish  these
symptoms  from  simulation.9
CRPS  often  occurs  in  several  family  members  and  at
younger  ages,  which  may  indicate  a  genetic  predisposition.
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ccordingly,  HLA  has  been  proposed  to  have  a  role  in  CRPS.
enetic  studies  have  also  identiﬁed  polymorphisms  in  the
NF-  gene  and  the  angiotensin  converting  enzyme  gene,
ut  no  contrasting  results  have  been  found  with  the  latter.10
Studies  have  shown  that  the  use  of  ACE  inhibitors  at
he  time  when  the  causal  trauma  is  suffered,  as  well  as
 medical  history  of  asthma  or  migraines,  is  associated
ith  an  increased  risk  of  developing  CRPS.  It  is  notewor-
hy  that  these  factors  imply  underlying  inﬂammation,  since
CE  inhibitors  increase  the  availability  of  substance  P,  and
oth  migraines  and  asthma  share  neurogenic  inﬂammation
echanisms.10
athophysiology
RPS  is  a  chronic  pain  condition  that  usually  arises  after
 traumatic  event  of  the  soft  tissues.  The  ‘‘deﬁnitive’’
ause  still  remains  unknown,  although  different  patho-
enetic  concepts  have  been  proposed;  three  of  the  most
tudied  are:  autonomic  dysfunction,  neurogenic  inﬂamma-
ion,  and  changes  in  CNS  neuroplasticity,  all  of  which  are
till  in  dispute.  However,  current  evidence  shows  that  this
roblem  could  have  a  multifactorial  origin.
utonomic  dysfunction
efers  to  an  alteration  of  the  sympathetic  nervous  system.
t  has  been  suggested  that  its  degree  depends  on  the  stage
n  which  the  syndrome  is  found.  This  suggests  the  exist-
nce  of  inhibition  of  sympathetic  vasoconstrictor  neurons,
xpressing  lower  levels  of  norepinephrine  in  the  affected
imb  compared  to  its  counterpart.  This  triggers  vasodilation,
nd  chronicity  of  this  condition  allows  vasoconstriction.
his  chronicity  contributes  to  a  redistribution  of  blood  ﬂow
hrough  arterioles,  causing  inadequate  capillary  nutrition,
hich  results  in  hypoxemia  and  acidosis.  These  alterations
an  produce  free  radicals,  which  cause  histopathological
hanges  by  oxidative  stress.
There  is  evidence  of  an  increase  in  the  number  of  -
drenergic  receptors  in  the  skin  of  patients  with  CRPS.
heir  activation  would  trigger  an  increase  in  noradrenaline
elease,  which  in  turn  produces  hyperstimulation  of  noci-
eptive  ﬁbers  causing  pain  and  hyperalgesia,  even  in
ympathectomized  patients.
Cutaneous  injection  of  norepinephrine  induces  pain  via
hese  adrenoreceptors  in  patients  who  respond  to  sympa-
hetic  blockade,  whereas  there  is  no  reaction  in  patients
ho  showed  no  response  to  the  blockade.  These  data  imply
hat  CRPS  may  involve  abnormal  adrenoreceptors  expressed
n  nociceptors  which,  when  stimulated  by  circulating  cat-
cholamines,  are  activated  and  cause  hyperalgesia  and
ossibly  alodinia.11
Another  group  of  researchers  found  that  in  CRPS  II,  nerve
amage  causes  an  upward  regulation  of  catecholamine
eceptors  (Fig.  1).
atecholamine  levelslasma  norepinephrine  levels  were  lower  in  the  affected
imb  compared  to  its  healthy  counterpart.  However
drenaline  levels  were  similar  in  both  extremities.6
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migure  1  Clinical  manifestations  of  CRPS  and  pathophysiolo-
ical  mechanisms  proposed  to  each.
nﬂammation
ecent  studies  suggest  the  existence  of  two  different
ources  of  inﬂammation:  Acute, tissue  damage  mediated
y  classical  inﬂammation  mechanisms  (IL-1,  IL-6,  TNF-
lpha,  CD4,  macrophages,  neutrophils)  and  neurogenic,
ediated  by  proinﬂammatory  cytokines  and  neuropeptides
eleased  directly  by  nociceptors  in  response  to  various
ausal  factors.8
The  following  are  related  substances:
ot  sympathetic  neurotransmitters
ubstance  P,  one  of  the  principal  pain  mediators  and  a
asodilator,  triggers  mast  cell  degranulation  and  activates
steoblasts.
The  calcitonin  gene-related  peptide  (CGRP)  is  a  vasodila-
or  that  plays  a  role  in  glandular  secretion,  is  involved
n  sensory  transmission,  and  stimulates  endothelial  cell
rowth.  Bradykinin  has  also  been  associated.
ympathetic  neurotransmitters
asoactive  intestinal  peptide  is  located  in  the  bones  and
romotes  bone  resorption,  in  addition  to  being  a  vasodila-
or  and  stimulating  sweat  gland  secretion.  Neuropeptide
 is  a  potent  vasoconstrictor  that  enhances  the  effects  of
drenaline.  It  is  the  most  abundant  peptide  in  the  CNS  and
6,8ts  periphery.
The  nociceptive  stimulus  not  only  causes  an  inﬂam-
atory  response,  but  also  a  low  pain  threshold.  Recent
esearch  has  shown  that  some  patients  respond  to
w
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reatment  with  immunoglobulins,  and  of  those,  most
arry  serum  IgG  autoantibodies  directed  against  autonomic
eceptors.12
ensitization
eripheral: After  tissue  injury,  local  primary  afferent  ﬁbers
elease  various  substances,  which  sensitize  nociceptive
erve  endings  to  other  substances  such  as  histamine  and
radykinin,  contributing  to  the  development  of  hyperalgesia
nd  allodynia.8 Sympathetic  denervation  causes  an  increase
n  the  sensitivity  of  blood  vessels  to  catecholamines,  pro-
uced  by  an  increase  in  the  number  or  sensitivity  of
drenoceptors.  This  increase  may  be  responsible  for  the
ecrease  in  blood  ﬂow  to  the  skin  in  chronic  conditions.  It
s  hypothesized  that  sympathectomy  causes  sensitization  in
he  long-term,  which  could  explain  why  some  patients  have
ransient  beneﬁts.
Central:  It  has  been  found  that  N-methyl  d-aspartate
NMDA)  receptors  play  an  important  role  in  central  sensitiza-
ion;  two  controlled  clinical  trials  showed  that  low  doses  of
etamine  (an  NMDA  antagonist)  dramatically  reduce  pain  in
atients  with  CRPS.13
Moreover,  electrical  stimulation  of  nociceptive
echanical-insensitive  ﬁbers  (CMiHI),  characterized  by
 large  electrical  excitation  threshold  and  innervation  of
ide  areas,  can  be  the  cause  of  secondary  hyperalgesia.
n  studies,  low-frequency  stimulation  caused  mechanical
yperalgesia  and  hypoesthesia,  whereas  high  frequency
timulation  generated  hypoalgesia  and  hypoesthesia.  It  was
lso  found  that  pain  itself  can  trigger  inhibitory  mechanisms
hich  develop  hypoalgesia;  this  type  of  pain  relief  is  known
s  ‘‘counter  irritation’’.14
icrovascular  pathology  of  soft  tissues
his  hypothesis  suggests  an  underlying  cause  in  muscle,
one  and  perineural  microvasculature  that  cuases  ischemia
nd  subsequent  inﬂammation  originating  persistent  abnor-
al  pain,  creating  central  sensitization.  Coderre  et  al.,
n  2004,  developed  a  mouse  model  that  they  called  CPIP
chronic  post-ischemia  pain),  which  involved  a  period  of
schemia-reperfusion  produced  by  placing  a  tourniquet  on
he  hind  leg  of  a  rat,  then  withdrawing  it  and  recording
heir  ﬁndings.  They  observed  a  reduction  in  the  density
f  sensory  ﬁbers  and  capillaries,  spontaneous  afferent  dis-
harge,  decreased  blood  ﬂow,  elevated  malondialdehyde
free  radical  product  of  lipid  peroxidation)  then,  when
ttenuated  by  antioxidants,  there  was  a  dose-dependent
mprovement  in  allodynia  in  the  animal.  They  also  observed
n  increase  in  the  production  of  proinﬂammatory  cytokines,
n  increase  in  lactate  levels  in  the  limb  subjected
o  ischemia-reperfusion  and  hypersensitivity  to  norepi-
ephrine;  symptoms  similar  to  some  patients  with  CRPS
ype  I.15
This  steady  state  of  inﬂammation  due  to  partial  or  inter-
ittent  ischemia  ended  up  causing  endothelial  dysfunction,
hich  could  explain  the  increase  in  constriction,  tissue
ypoxia,  metabolic  acidosis,  and  increased  permeability  to
acromolecules.  Chronic  ischemia  can  also  lead  to  a  state  of
apillary  ‘‘no-reﬂow’’  where  the  decrease  in  vessel  lumen  is
AA
e
c
w
t
4
t
o
a
h
a
a
F
b
(
w
a
b
e
c
p
a
n
t
w
C
c
i
T
p
a
i
h
p
b
(
D
T
i
c
d
i
l
c
a
m
n
a
tComplex  regional  pain  syndrome  (CRPS),  a  review  
not  only  functional,  but  also  physical;  this  could  also  explain
why  some  patients,  after  undergoing  sympathetic  blockade,
do  not  improve.7
Central  changes
Neuroplasticity:  Janin  and  Baron  were  the  ﬁrst  to  suggest  a
central  origin  in  the  pathophysiology  of  CRPS.  It  is  currently
known  that  chronic  pain  can  create  a  change  in  the  cortical
representation  of  the  affected  area,  in  particular,  the  repre-
sentation  of  the  affected  area  or  limb  in  the  somatosensory
cortex  (S1)  which  is  relatively  small  compared  to  the  healthy
limb.8
Spinal  neurons  may  increase  their  sensitivity  in  response
to  nociceptive  bombardment  caused  by  autonomic  changes.
A  reorganization  of  the  primary  somatosensory  area  can
be  generated  in  the  supraspinal  space,  as  in  amputee
patients,  demonstrated  by  MRI;  due  to  this,  it  is  said
that  peripheral,  spinal,  and  supraspinal  nociceptive  cor-
tical  processing  scales  are  involved  in  the  genesis  of
CRPS.5
It  is  recognized  that  this  neuronal  plasticity,  induced
by  pain,  causes  hyperalgesia  but  it  can  also  cause
hypoalgesia  and  hypoesthesia.  Several  studies  show  that
neuronal  plasticity  may  be  a  decline  effect  in  response  to
pain.14
Altered  functional  connectivity  in  the  resting  state
In  recent  years,  there  have  been  several  studies  regarding  an
alteration  in  the  interconnections  of  different  brain  regions
in  patients  with  CRPS.  This  is  based  on  previous  research
of  chronic  pain  that  has  demonstrated  a  spatiotemporal  dis-
ruption  in  functional  connectivity  at  rest,  also  known  as  DMN
(default  mode  network),  which  shows  an  increase  in  diffuse
interconnections,  unlike  control  groups.  These  areas  show  a
proportional  correlation  to  the  intensity  of  pain  experienced
by  patients.16
Dysfunction  in  the  motor  cortex
Because  pain  can  interfere  with  the  processing  of  afferent
signals  that  contribute  to  the  sense  of  positioning,  and  the
mental  image  of  the  affected  limb  is  distorted  in  patients
with  CRPS,  proprioception  could  be  signiﬁcantly  affected.
There  are  observations  that  these  patients  need  to  carefully
look  at  their  affected  limb  to  control  movements,  making
it  possible  for  them  to  compensate.17 However,  more  and
better  studies  are  required  to  have  consistent  evidence,
since  the  only  signiﬁcant  fact  that  has  been  found  is  an
area  of  spatial  representation  of  S1  lower  on  the  side  of  the
affected  limb,  unlike  its  healthy  counterpart  or  in  control
groups.18
Clinical manifestationsThe  onset  of  clinical  manifestations  may  be  hours  or  even
months  after  the  noxious  event,  characteristically  they
includes  a  triad  of  autonomic,  sensory  and  motor  abnormal-
ities.
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utonomic  alterations
mong  these  alteration  we  can  ﬁnd  early  onset  distal
dema  (in  its  soft  and  congestive  form)  in  up  to  80%  of
ases,  as  well  as  changes  in  skin  color  and  temperature,
hich  is  reddish  and  hyperemic  (≥1 ◦C  in  comparison  to
he  other  limb),  usually  in  the  early  stages;  however,  in
0%  of  cases  it  can  progress  with  decreased  skin  tempera-
ure  and  pallor.  Sudomotor  phenomena,  such  as  hypohidrosis
r  hyperhidrosis  (the  latter  being  the  most  common)  are
lso  seen;  trophic  changes,  which  can  present  as  excessive
air  growth,  thin  nails,  and  skin  atrophy,  evidenced  by  the
ppearance  of  ‘‘glowing’’  skin,  thinning  of  the  epidermis
nd  muscle  atrophy,  as  well  as  contractures,  are  also  found.
inally,  another  alteration  that  is  present  in  some  cases  is
one  atrophy,  which  can  be  associated  with  osteoporosis
Figs.  2  and  3).
The  main  and  most  common  symptom  (90%)  is  pain,
hich  is  described  as  burning  or  stinging.  It  is  usually  felt
s  deep  (68%)  rather  than  superﬁcial  (32%)  pain.  It  can
e  exacerbated  after  temperature  changes,  exercise  or
pisodes  of  stress  and/or  anxiety,  and  there  have  been
ases  where  it  increases  at  night.  Pain  is  often  accom-
anied  by  other  phenomena  such  as  hyperalgesia  and
llodynia.  Of  these  the  most  important  is  muscle  weak-
ess;  other  manifestations  in  this  category  are  essential
remors  in  the  affected  limb,  myoclonus  and  dystonia,
hich  is  most  frequently  observed  in  patients  with  type  II
RPS.
It  is  important  to  remember  that  the  manifestations  may
hange  depending  on  the  location  of  the  condition.  Prox-
mal  and  deep  joints  undergo  a  reduction  in  function.19
his  differs  from  other  neuropathic  syndromes  due  to  the
resence  of  edema,  vasomotor  and  sudomotor  changes,  in
ddition  to  an  orthostatic  component  which  is  reduced  in
ntensity  when  the  limb  is  raised,  and  increased  when  it  is
eld  down.5 It  was  thought  that  CRPS  could  have  a temporal
rogression  of  symptoms;  however,  this  idea  was  rejected
y  the  International  Association  for  the  Study  of  Pain
IASP).1
iagnosis
here  are  no  pathognomonic  signs  or  symptoms  and  there
s  no  deﬁnitive  diagnostic  test.  Diagnosis  is  based  on  a
omplete  medical  history  that  includes  the  severity  and
uration  of  symptoms  and  signs,  fracture  type  and  sever-
ty  of  the  injury  and  physical  examination  of  the  affected
imb.20
The  IASP  published  a  review  of  the  clinical  diagnostic
riteria  in  2007  called  the  ‘‘Budapest  Criteria’’,  which  has
 sensitivity  of  85%  and  a  speciﬁcity  of  69%  (Table  1).  There
ust  be  regional  pain  that  exceeds  a dermatome  or  a  single
erve  territory,  continuous  or  evoked  pain  of  an  intensity
nd/or  duration  disproportionate  to  the  trauma  or  injury
hat  may  have  caused  it,  and  which  is  associated  with  a
ange  of  symptoms  and  signs  of  sensory,  motor,  vasomotor,
udomotor  and  trophic  disturbances.  Symptoms  and  signs
an  be  variable  depending  on  the  time  of  evolution  of  the
yndrome.4 There  are  other  approaches  to  the  diagnosis,
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Table  1  IASP  Diagnostic  criteria  for  complex  regional  pain  Syndrome  (2007  Budapest  criteria).
1.  Continuous  pain  disproportionate  to  the  event  that  caused  it
2. Symptoms  (must  meet  at  least  one  symptom  in  three  of  the  four  categories)
Sensory:  hyperesthesia  and/or  allodynia
Vasomotor:  asymmetry  in  skin  temperature  and/or  asymmetry  of  skin  color  and/or  changes  in  skin  color
Sudomotor:  edema  and/or  sweating  changes  and/or  asymmetric  sweating
Motor: decreased  range  of  motion  and/or  motor  dysfunction  (tremor,  dystonia,  weakness)  and/or  trophic  changes  (skin,
hair, nails)
3.  Signs  (must  meet  at  least  one  sign  in  two  or  more  of  the  four  categories)
Sensory:  evidence  of  hyperalgesia  (to  puncture)  and/or  allodynia  (touch/temperature/deep  pressure/joint  movement)
Vasomotor: asymmetry  in  skin  temperature  >1 ◦C  and/or  asymmetry  of  skin  color  and/or  changes  in  skin  color
Sudomotor:  evidence  of  edema  and/or  sweating  changes  and/or  asymmetric  sweating
Motor: evidence  of  decreased  range  of  motion  and/or  motor  dysfunction  (tremor,  dystonia,  weakness)  and/or  trophic
changes (skin,  hair,  nails)
4.  Rule  out  other  conditions  that  may  explain  the  previous  symptoms  and  signs.
Figure  2  (a)  Female  patient  with  right  upper  limb  CRPS  affected  before  treatment.  (b)  Same  patient  with  hyperemic,  shiny  bow
a ma,  during  initiation  of  treatment  with  infusion  pump  (Ropivacaine
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jnd decreased  range  of  motion  secondary  to  the  presence  of  ede
%/20 days22).
uch  as  the  diagnostic  criteria  of  Kozin  (Table  2)  and  Veldman
Table  3).
omplementary  tests
adiography
n  ill-deﬁned  subchondral  heterogeneous  ‘‘mottled’’  dem-
neralization  of  varying  intensity  is  observed  with  a
ensitivity  of  73%  and  a  speciﬁcity  of  57%,  maintaining  a
egional  character  in  later  stages  of  the  disease.20
ammagraphy
his  study  is  recommended  in  stages  I  and  II  with  a  sensitivity
f  97%  and  a  speciﬁcity  of  86%.  Its  main  use  is  for  the  early
iagnosis  of  CRPS.  In  the  initial  stages,  intense  and  early
one  hyper-uptake  that  exceeds  the  limits  of  the  affected
oint  is  seen.20
Figure  3  Female  with  upper  member  CRPS  affected,  poste-
rior entitled  to  20  days  of  completing  treatment  with  infusion
pump to  the  infraclavicular  brachial  plexus  (Ropivacaine  2%22).
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Table  2  Kozin  diagnostic  criteria.
1.  Pain  and  tenderness  of  a  limb
2. Symptoms  or  signs  of  unsteadiness
Raynaud’s  Phenomenon
Cold,  pale  skin
Hot  or  erythematous  skin
Hyperhidrosis
3.  Swelling  of  limb
Edema  with  or  without  fovea
4. Trophic  skin  changes
Atrophy
Desquamation
Hypertrichosis
Hair  loss
Nail  changes
Thickening  of  the  palmar  aponeurosis
Table  4  Differential  diagnosis  of  CRPS.
•  Deep  vein  thrombosis
• Thrombophlebitis
• Cellulite
• Lymphedema
• Vascular  insufﬁciency
•  Infectious  arthritis
• Rheumatoid  arthritis
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(Deﬁned: meets 4 criteria; probable: meets criteria 1, 2, and 3;
possible: meets criteria 1 and 2.
Magnetic  resonance  imaging
This  method  provides  a  differential  diagnosis  with
osteonecrosis,  especially  of  the  hip.  It  also  provides
information  about  bone  marrow  edema,  alteration  of  soft
tissue,  and  the  presence  of  joint  effusion.6
Skin  ﬂuximetry  by  the  laser  doppler  technique
This  is  one  of  the  most  precise  techniques  that  are  currently
available  for  the  early  diagnosis  of  CRPS  I.  It  provides  infor-
mation  of  changes  in  ﬂow,  volume  and  velocity  of  cutaneous
microvascularity  in  CRPS  I  in  stages  I  and  II.
Thermography
An  increase  in  local  temperature,  especially  in  the  ﬁrst
weeks  of  development,  is  found,  although  this  is  not  a  con-
sistent  ﬁnding  (sensitivity  45%).21
Differential  diagnosis
The  differential  diagnosis  will  depend  on  the  stage  of  evo-
lution.  In  the  initial  phase,  infectious  arthritis,  rheumatic
arthritis,  inﬂammatory  joint  disease,  peripheral  arterial
disease  and  deep  vein  thrombosis  should  be  considered.
In  the  chronic  phase,  Dupuytren’s  disease,  scleroderma,
Table  3  Veldman  diagnostic  criteria.
1  The  presence  of  4--5  of  the  following:
Unexplained  diffuse  pain
A difference  in  skin  color  in  relation  to  another  extremity.
Diffuse  edema
A difference  in  skin  temperature  relative  to  another
extremity.
Limited  range  of  active  motion.
2. Occurrence  or  increase  in  the  above  signs  and  symptoms
after  use.
3.  The  above  signs  and  symptoms  are  present  in  a  larger
area  than  the  primary  area  of  injury  or  operation  and
includes  the  area  distal  to  the  primary  lesion.
i
c
l
c
m
t
c
f
t
t
p
(
i
C
d
a
a
e•  Inﬂammatory  arthropathy
• Dupuytren’s  disease
nd  plantar  fasciitis  should  be  taken  into  account.  In  hip
onditions,  osteonecrosis  and  coxitis  should  be  ruled  out.  If
here  is  bone  demineralization,  it  would  be  recommended
o  rule  out  osteoporosis  and  bone  tumors  (Table  4).20
reatment
arly  treatment  is  necessary  to  achieve  complete  recovery
nd  prevent  damage.  Treatment  of  CRPS  requires  a  multidis-
iplinary  approach  to  pain  management  which  is  also  aimed
t  functional  recovery  of  the  affected  limb.
harmacotherapy
onsteroidal  antiinﬂammatory  drugs  (NSAIDs),  corticoste-
oids,  cyclooxygenase  (COX)  2  inhibitors  and  free  radical
cavengers  are  used  with  the  intention  of  treating  pain  in
ddition  to  the  inﬂammatory  process  in  CRPS.  However,
nﬂammation  in  CRPS  may  be  largely  neurogenic  (initiated
y  inﬂammatory  mediators  of  the  terminals  of  afferent  noci-
eptors)  and  no  drug  has  been  studied  for  this  type  of
nﬂammation.22
NSAIDs  represent  ﬁrst-line  treatment,  especially  in  the
arly  stages  and  at  non-specialized  units,  although  their
fﬁcacy  speciﬁcally  for  CRPS  is  unproven,  and  they  are
ot  prescribed  in  the  treatment  of  neuropathic  pain.  In
nitial  phases  they  can  be  prescribed  for  treatment  of
nﬂammation.23
Oral  corticosteroids  are  the  only  anti-inﬂammatory  drugs
or  which  there  is  direct  evidence  from  CRPS  clinical  trials
evidence  level  1).  Most  trials  included  acute  cases,  when
nﬂammation  is  more  common,  and  it  is  unknown  if  corti-
osteroids  offer  a  similar  beneﬁt  for  chronic  CRPS,  where
evels  of  proinﬂammatory  cytokines  are  lower,  or  in  CRPS
ases  with  only  mild  inﬂammation.  A  short  course  of  steroids
ay  be  indicated  early  in  CRPS  with  prominent  inﬂamma-
ion,  but  in  longer  courses  there  are  contraindications  to
hronic  use  of  steroids.22
Both  minor  (tramadol)  and  major  (morphine,  oxycodone,
entanyl,  hydromorphone,  buprenorphine)  opioids  have
heir  place  in  moderate-severe  pain  that  is  difﬁcult  to  con-
rol,  and  they  have  demonstrated  efﬁcacy  in  neuropathic
ain.4
Antiepileptics  (gabapentin)  and  tricyclic  antidepressants
amitriptyline)  and  pregabalin  have  been  used  as  adjuvants
n  the  treatment  of  CRPS.  There  are  no  controlled  trials  of
RPS  type  I  with  these  drugs,  but  their  efﬁcacy  has  been
emonstrated  in  the  treatment  of  neuropathic  pain.  These
ct  by  inhibiting  pain  pathways  and  neuronal  plasticity,  and
re  prescribed  in  acute  phases  with  nerve  injury,  nerve
ctopic  activity  or  chronic  phases.4
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Free  radical  scavengers  have  shown  some  efﬁcacy  in
he  prevention  and  treatment  of  CRPS,  although  in  acute
hases  and  with  moderate  involvement.  Vitamin  C  at  doses
f  500  mg/day  and  N-acetyl  cysteine  at  600  mg/day  have
hown  efﬁcacy  in  the  prevention  of  CRPS  in  patients  who
ave  suffered  wrist  fractures.  Dimethyl  sulfoxide  50%  cream
eems  to  reduce  pain  and  inﬂammation  of  the  limb  in  the
cute  phase.4
There  is  evidence  that  several  bisphosphonates  have  an
cceptable  safety  proﬁle  and  can  signiﬁcantly  relieve  spon-
aneous  pain  and  improve  the  functional  status  of  patients
ith  an  early  disease  (duration  of  6  months)  and  with
n  abnormal  uptake  on  the  3-phase  bone  scan.  There  are
ndications  that  the  doses  necessary  to  achieve  long-term
emission  are  very  high,  i.e.,  neridronate  at  100  mg  or
amidronate  at  90  mg,  each  given  via  IV  four  times  over
 period  of  10  days.  Bisphosphonates  have  analgesic  prop-
rties  that  go  beyond  their  effect  on  bone  metabolism,
nd  preclinical  data  suggest  that  they  have  antinociceptive
ffects  in  animal  models  of  neuropathic  pain.  Therefore,
heir  efﬁcacy  cannot  be  limited  to  patients  with  CRPS-
elated  bone  pain,  but  relevant  clinical  data  are  not  yet
vailable.9
The  recent  use  of  ketamine,  a  potent  agonist  of  N-
ethyl-d-aspartate  (NMDA),  in  the  management  of  CRPS-I,  is
ue  to  the  phenomenon  of  central  sensitization.  This  central
ensitization  is  expressed  mainly  in  the  ﬁrst  relay  of  nocicep-
ive  information  integration,  where  the  synapses  formed  by
he  central  ends  of  the  A  and  C  ﬁber  nociceptors  to  noci-
eptive  neurons  in  the  dorsal  horn  of  the  spinal  cord  are
ery  active.  Several  ketamine  dosing  schemes  have  been
ested,  from  transcutaneous  application  to  coma  induced  by
etamine.  Although  lower  doses  seem  to  provide  the  best
esults,  the  lack  of  regulatory  approval  for  this  indication
nd  various  side  effects  limit  the  use  of  ketamine  in  current
ractice.8
Topical  anesthetics  such  as  lidocaine  cream  or  transder-
al  absorption  patches  at  5%,  can  be  suitable  in  cases  of
llodynia  and/or  hyperalgesia.22
nterventional  techniques
ympathetic  nerve  block  is  a  treatment  option  for  patients
ho  are  refractory  to  pharmacological  treatments,  espe-
ially  when  performed  early  in  the  course  of  the  disease.24
erve  blockage  improves  short-term  pain  and  joint  mobility
nd  its  effectiveness  is  greater  when  performed  in  the  early
tages  of  the  disease,  although  there  are  few  reliable  studies
nd  a  few  controlled  studies  that  have  failed  to  demonstrate
ong-term  efﬁcacy.  Blockage  provides  a  pain-free  period  that
mproves  limb  mobility,  allowing  performance  of  intensive
hysiotherapy,  especially  when  using  continuous  techniques,
uch  as  local  anesthetic  infusion  via  an  auxiliary  or  lumbar
pidural  catheter.4
Some  uncontrolled  studies  have  shown  initial  improve-
ent  in  pain  after  percutaneous  sympathectomy,  but  there
s  a  high  risk  of  recurrence  between  6  months  and  2  years,
ith  neuralgia  and  post-sympathectomy  pain  (up  to  10%.).9
Placement  of  a  cervical  or  lumbar  spinal  epidural  neu-
ostimulator  for  posterior  column  spinal  cord  stimulation
ay  be  an  option  in  severe  disabling  pain  in  CRPS  cases  thatS.  Castillo-Guzmán  et  al.
ave  not  responded  to  other  treatments.  A  study  of  36  cases
howed  efﬁcacy  in  reducing  pain  and  improving  quality  of
ife  in  both  the  short  and  long  term.4
A  retrospective  study  found  that  intramuscular  injection
f  botulinum  toxin  A  (BTXA)  in  waist  muscles  of  the  upper
imb  was  beneﬁcial  for  short-term  relief  of  pain  caused  by
RPS.  There  was  a 43%  reduction  in  local  pain  scores  4  weeks
fter  intramuscular  injections  of  BTXA.  Studies  that  prove  its
fﬁcacy  and  support  its  use  in  the  long-term  treatment  of
RPS  are  still  lacking.25
ehabilitation
arly  rehabilitation  is  essential  to  try  to  prevent  muscle
trophy  and  contractures,  which  in  extreme  cases  can  be
rreversible,  although  it  requires  the  active  participation  of
he  patient  and  this  is  not  always  possible  due  to  severe  pain
nd  associated  psychological  disorders.
Physical  therapy  can  reduce  pain  and  improve  limb
obility,  although  the  intensity  of  treatment  varies  depend-
ng  on  the  severity  of  the  syndrome.  Lymphatic  drainage
an  improve  edema.  Transcutaneous  electrical  stimulation
TENS)  may  improve  pain,  although  its  use  is  not  recom-
ended  in  patients  with  severe  allodynia  or  hyperalgesia.
ccupational  therapy  can  also  enhance  limb  function  and
oordination.
Some  studies  suggest  that  mirror  therapy  may  have  a  role
n  the  treatment  of  CRPS.  The  patient  performs  the  exercises
n  front  of  a  mirror,  perpendicular  to  the  midline,  which
nly  allows  him/her  to  observe  the  unaffected  limb  during
reatment;  this  creates  a  sense  of  normality  of  the  affected
imb,  probably  due  to  activation  of  the  frontal  cortex,  and
ain  relief,  especially  in  acute  phases  of  the  disease.26
onclusion
lthough  the  exact  causes  of  CRPS  have  not  yet  been  discov-
red,  the  progress  made  in  recent  years  in  the  understanding
f  the  pathophysiological  mechanisms  involved  in  the  dis-
ase  allow  us  to  foresee  new  treatment  options  targeting  the
tiology.  Understanding  the  etiological  factors  will  lead  to  an
arly  diagnosis  and  a  better  implementation  of  treatment.
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